REFERENCES
- Masaki Y, Dong L, Kurose N, et al. Proposal for a new clinical entity, IgG4-positive multiorgan lymphoproliferative syndrome: analysis of 64 cases of IgG4-related disorders. Ann Rheum Dis. 2009;68(8):1310–1315.
- Kubota T, Moritani S, Katayama M, et al. Ocular adnexal IgG4-related lymphoplasmacytic infiltrative disorder. Arch Ophthalmol. 2010;128(5):577–584.
- Khosroshahi A, Bloch DB, Deshpande V, et al. Rituximab therapy leads to rapid decline of serum IgG4 levels and prompt clinical improvement in IgG4-related systemic disease. Arthritis Rheum. 2010;62(6):1755–1762.
- Mehta M, Jakobiec F, Fay A. Idiopathic fibroinflammatory disease of the face, eyelids and periorbital membrane with immunoglobulin G4-positive plasma cells. Arch Pathol Lab Med. 2009;133:1251–1255.
- Umehara H, Okazaki K, Masaki Y, et al. Comprehensive diagnostic criteria for IgG4-related disease (IgG4-RD), 2011. Mod Rheumatol. 2012 Feb;22(1):21–30.
- Stone JH; Zen Y, Deshpande V. IgG4-related disease. N Engl J Med. 2012; 366:539–555.
- Wallace Z, Khosroshahi A, Jakobiec F, et al. IgG4-related systemic disease as a cause of ‘‘idiopathic’’ orbital inflammation, including orbital myositis, and trigeminal nerve involvement. Surv Ophthalmol. 2012 Jan 2;57(1):26–33.
- Cheuk W, Chan JK. IgG4-related sclerosing disease: a critical appraisal of an evolving clinicopathologic entity. Adv Anat Pathol. 2010;17:303–332.
- Van den Brande JM. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn’s disease. Gastroenterology. 2003 Jul;124(7):1774–1785.